Double-Digit Revenue Growth
Dr. Reddy's Laboratories reported a steady double-digit revenue growth of 11% year-over-year, driven by strong performance across most markets, excluding the U.S. generics business.
EBITDA Margin Exceeds Expectations
The company achieved an EBITDA margin of 26.7%, surpassing their aspiration of 25%.
Biosimilar Business Momentum
The biosimilar business gained momentum due to strategic collaboration with Alvotech for co-development, manufacturing, and commercialization of pembrolizumab.
Carbon Disclosure Project Rating
Dr. Reddy's Laboratories received an 'A' rating in the climate category from the Carbon Disclosure Project, making it the only Indian pharmaceutical company with this score.
Indian Market Performance
The India business reported double-digit growth of 11% year-on-year, driven by new products and pricing. The company maintained its position as the 10th largest player in the Indian pharmaceutical market.